Anavex Life Sciences Corp (AVXL)

[Anshu2]

The biomarker data is CERTAINLY a very positive information. But incompleteness — raises many doubts (is the change clinically meaningful? Why aren’t they disclosing that information? What about other biomarkers?)

Also — flip-flop of cog etc — also comes across as shady, and perhaps raises other questions.

So — these are the problems in the data being approval worthy (or at least the market being skeptical of it). But certainly hope that an appropriate P3 can be designed with good chance of success perhaps??